Business
Traws Pharma Reports First Quarter 2025 Results and Business Highlights
FDA briefing document submitted April 24, 2025 in support of a meeting to align on pathway for tivoxavir marboxil (TXM, bird flu/seasonal flu) including potential for accelerated approval utilizing the “Animal Rule” Additional briefing document in support of a meeting to align on ratutrelvir for COVID - including Long COVID - to be submitted to regulatory authorities in Q2 2025 Cash runway to support planned operations into Q1 2026 NEWTOWN, Pa., May 15, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc
About this update from Traws Pharma, Inc.
[{"type":"image","alt":"Traws Pharma, Inc.","displaySize":"","headline":null,"caption":"Traws Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/b7f59076ee694ac5fc5d681bbcfa7af2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/O38eCot9fjUiIRrtl6lHyg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b7f59076ee694ac5fc5d681bbcfa7af2","width":300,"height":300}},"lazy":false},{"type":"text","content":"FDA briefing document submitted April 24, 2025 in support of a meeting to align on pathway for tivoxavir marboxil (TXM, bird flu/seasonal flu) including potential for accelerated approval utilizing the “Animal Rule”","length":215,"tagName":"p"},{"type":"text","content":"Additional briefing document in support of a meeting to align on ratutrelvir for COVID - including Long COVID - to be submitted to regulatory authorities in Q2 2025","length":165,"tagName":"p"},{"type":"text","content":"Cash runway to support planned operations into Q1 2026","length":54,"tagName":"p"},{"type":"text","content":"NEWTOWN, Pa., May 15, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today reported financial results for the quarter ended March 31, 2025 and provided recent business highlights, with updates to the Company’s investigational programs including lead product candidate, tivoxavir marboxil (TXM) in development for bird flu and seasonal flu, and ratutrelvir in development for acute treatment of COVID, with potential to prevent COVID-rebound and Long COVID.","length":658,"tagName":"p"},{"type":"text","content":"“Traws continues to make excellent progress this year with its two proprietary, investigational oral, small molecule antivirals for bird flu/seasonal flu and COVID. Identifying opportunities to accelerate the path to approval is core to Traws’ strategy. We are preparing to interact with regulatory authorities in the coming months regarding both of our antiviral programs,” said Iain D. Dukes, D.Phil, Interim CEO of Traws Pharma. “We have submitted briefing materials to the FDA for our tivoxavir marboxil program, in preparat...